CD44 and cancer: Our results, shown in Figure 4F,G, also verified that TCCM enhanced the EMT process and helped cancer cells gain stem-like properties, as evidenced by the expression of cancer stemness markers (CD133, CD44, SOX2, and ALDH), whereas diHEP-DPA reversed this effect.